ERBIN functions as a critical adapter protein that regulates receptor signaling and inflammatory responses in epithelial cells. Its primary role involves binding to the unphosphorylated tyrosine-1248 residue of ERBB2 receptor, potentially stabilizing this inactive state and modulating ERBB2 signaling 1. ERBIN acts as a negative regulator of inflammatory pathways by inhibiting NOD2-dependent NF-κB signaling and reducing pro-inflammatory cytokine secretion 1. The protein also plays important roles in cellular adhesion and cytoskeletal organization through its localization at cell junctions, hemidesmosomes, and basement membranes. ERBIN deficiency has significant disease implications, particularly in cancer progression where it functions as a tumor suppressor. In glioblastoma, ERBIN expression is epigenetically silenced by RAS signaling, and its restoration inhibits RAS-mediated proliferation and invasion 2. In platelets and megakaryocytes, ERBIN regulates mitochondrial function and immune responses, with knockout promoting B cell-mediated antitumor immunity 3. Clinically, ERBIN mutations cause rare primary atopic disorders characterized by allergic disease and connective tissue abnormalities, likely through enhanced TGFβ signaling pathways 1. ERBIN has also emerged as a potential target for cancer immunotherapy, with mutation-specific CD4+ T cells recognizing ERBIN variants showing therapeutic efficacy in cholangiocarcinoma 4.